Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer¶
Why this mattered¶
Before this study, PD-1 blockade in lung cancer was clinically promising but biologically difficult to predict: responses could be dramatic and durable, yet only a subset of patients benefited. Rizvi and colleagues helped shift the field from viewing checkpoint response mainly through tumor histology or PD-L1 staining toward a genomic model of immunotherapy sensitivity. By showing that higher nonsynonymous mutation burden, smoking-associated mutational signatures, and predicted neoantigen load correlated with response and durable benefit, the paper gave a mechanistic explanation for why some non–small cell lung cancers were especially vulnerable to PD-1 blockade: they carried more tumor-specific mutations that could be recognized by T cells once inhibitory signaling was relieved.
The importance was not simply that mutation burden was associated with response, but that the study made tumor genomics clinically actionable for immunotherapy. Whole-exome sequencing could be used to connect a cancer’s mutational history to immune recognition, progression-free survival, and objective response. The observation that neoantigen-specific CD8+ T cell responses tracked tumor regression in a responder linked the statistical association to a plausible immune mechanism, strengthening the idea that checkpoint inhibitors work in part by amplifying pre-existing or inducible T cell responses against tumor neoantigens.
This paper became one of the foundations for later biomarker-driven immuno-oncology. It helped motivate broader use and testing of tumor mutational burden, neoantigen prediction, mismatch-repair deficiency, and other genomic correlates of checkpoint sensitivity across cancer types. Subsequent work refined and complicated the picture, showing that mutation burden alone is imperfect and context-dependent, but the paradigm endured: the effectiveness of immune checkpoint blockade depends not only on the drug or the immune system in isolation, but on the evolutionary and mutational architecture of the tumor itself.
Abstract¶
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non-small cell lung cancers treated with pembrolizumab, an antibody targeting programmed cell death-1 (PD-1). In two independent cohorts, higher nonsynonymous mutation burden in tumors was associated with improved objective response, durable clinical benefit, and progression-free survival. Efficacy also correlated with the molecular smoking signature, higher neoantigen burden, and DNA repair pathway mutations; each factor was also associated with mutation burden. In one responder, neoantigen-specific CD8+ T cell responses paralleled tumor regression, suggesting that anti-PD-1 therapy enhances neoantigen-specific T cell reactivity. Our results suggest that the genomic landscape of lung cancers shapes response to anti-PD-1 therapy.
Related¶
- cite → PD-1 blockade induces responses by inhibiting adaptive immune resistance — The NSCLC PD-1 study cites adaptive immune resistance as the biological mechanism explaining why PD-1 blockade can restore antitumor T-cell activity.
- cite → Improved Survival with Ipilimumab in Patients with Metastatic Melanoma — The NSCLC PD-1 study cites ipilimumab as clinical evidence that immune checkpoint blockade can improve survival in cancer.
- cite → Fast and accurate short read alignment with Burrows–Wheeler transform — The NSCLC PD-1 study uses BWA-style Burrows-Wheeler short-read alignment for sequencing-based mutation detection.
- cite → Signatures of mutational processes in human cancer — The NSCLC PD-1 study links smoking-associated mutational signatures to tumor mutation burden and immunotherapy sensitivity.
- cite → Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer — The NSCLC PD-1 study builds on early anti-PD-1 clinical evidence showing activity and immune correlates across cancers.
- cite → A framework for variation discovery and genotyping using next-generation DNA sequencing data — The NSCLC PD-1 study relies on GATK-style variant discovery and genotyping for next-generation sequencing mutation calls.
- cite ← Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade — The 2017 mismatch-repair paper links high mutation burden from repair deficiency to the neoantigen sensitivity to PD-1 blockade shown in lung cancer.
- cite ← PD-1 Blockade in Tumors with Mismatch-Repair Deficiency — PD-1 blockade in mismatch-repair-deficient tumors uses the same neoantigen-burden claim that high somatic mutation load predicts response to PD-1 inhibition.
- cite ← Pembrolizumab versus Ipilimumab in Advanced Melanoma — The pembrolizumab melanoma trial cites tumor mutational burden evidence linking neoantigen load to sensitivity to PD-1 blockade.
- cite ← Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer — Both papers connect PD-1 blockade response in non-small-cell lung cancer to tumor mutational burden and neoantigen load.
- cite ← Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer — The nivolumab lung-cancer trial connects to mutational-landscape work through the claim that tumor mutation burden influences sensitivity to PD-1 blockade.
- cite ← Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer — The nivolumab trial cites mutational-landscape work because tumor mutational burden was proposed as a predictor of sensitivity to PD-1 blockade in non-small-cell lung cancer.
- enables ← Improved Survival with Ipilimumab in Patients with Metastatic Melanoma — Ipilimumab proved checkpoint blockade could improve melanoma survival, supporting the broader immunotherapy framework used to link tumor mutational burden with PD-1 response.
- enables ← Fast and accurate short read alignment with Burrows–Wheeler transform — BWA enabled efficient alignment of sequencing reads, a prerequisite for calling somatic mutations used to associate lung-cancer mutational burden with PD-1 blockade sensitivity.